This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch
by Ryan McQueeney
Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.
Top-Ranked Healthcare ETFs for Long-Term Investors
by Neena Mishra
Healthcare is now the best-performing sector of 2018. We highlight two top-ranked ETFs suitable for long-term investors.
Stock Market News For Oct 17, 2018
by Zacks Equity Research
Wall Street rebounded on Tuesday as stocks surged across the board due to strong third-quarter 2018 earnings results and impressive economic data.
This Week's Most Spectacular Earnings Charts
by Tracey Ryniec
It doesn't get much better than these five big cap companies with their outstanding earnings surprise records and great earnings charts.
Will Tuesday's Earnings Reports Inspire a Stock Market Rebound?
by Ryan McQueeney
Ryan McQueeney recaps the morning's top pre-market earnings reports from Goldman Sachs, Morgan Stanley, and Johnson & Johnson. Later, he is joined by Zacks Strategist Dave Bartosiak to discuss upcoming reports from Netflix and IBM.
Q3 Earnings Reports: MSFT, NFLX, GS, MS, UNH, JNJ
by Zacks Equity Research
Q3 Earnings Reports: MSFT, NFLX, GS, MS, UNH, JNJ
Q3 Earnings Results Impress: GS, MS, UNH & More
by Mark Vickery
Q3 earnings reports are hitting the tape fast and furious at this hour. We will take this opportunity to summarize a handful of them.
J&J (JNJ) Beats Earnings & Sales Estimates in Q3, Ups View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the third quarter of 2018 and raises full-year forecast.
Johnson & Johnson (JNJ) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.99% and 2.19%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
JPMorgan, Wells Fargo, Citigroup, Johnson & Johnson, Netflix and Schlumberger are part of Zacks Earnings Preview
by Zacks Equity Research
JPMorgan, Wells Fargo, Citigroup, Johnson & Johnson, Netflix and Schlumberger are part of Zacks Earnings Preview
Friday Bounce Ends a Volatile Week for Stocks
by David Borun
Interest rates fears fuel the biggest weekly decline in 7 months
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
by Zacks Equity Research
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
by Zacks Equity Research
Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
Is a Surprise Coming for Johnson & Johnson (JNJ) This Earnings Season?
by Zacks Equity Research
Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Bristol-Myers Inks Deal and Invests $12 Million in Compugen
by Zacks Equity Research
Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.
Dow 30 Stock Roundup: Walgreens' Earnings Top, UTX Board OKs Dividend Hike
by Swarup Gupta
The index suffered a particularly dismal week, weighed down by surging bond yields.
Banks Provide Positive Start to Q3 Earnings Season
by Sheraz Mian
The banking sector's earnings growth picture is tracking above historical periods, while revenue growth is modest and in-line with recent trends.
J&J (JNJ) to Set the Ball Rolling for Pharma Q3 Earnings
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales is likely to continue in the third quarter.
Johnson & Johnson (JNJ) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $137.73, moving -1.06% from the previous trading session.
J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study
by Zacks Equity Research
J&J's (JNJ) Stelara induces clinical remission and response in ulcerative colitis patients who had failed prior therapy, per data from a phase III study.
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
by Zacks Equity Research
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
Johnson & Johnson (JNJ) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J Inks Deal With Arrowhead for Promising Liver Candidate
by Zacks Equity Research
Johnson & Johnson (JNJ) signs a licensing pact with Arrowhead to develop the latter's RNAi therapy candidate, ARO-HBV, for treating chronic hepatitis B viral infection. The deal is worth $3.7 billion.
Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data
by Zacks Equity Research
Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.
Bull of the Day: Roche (RHHBY)
by Kevin Cook
With 3 of the top-ten cancer drugs globally, this Swiss giant is looking for the next I/O breakthroughs